,Clinical Observation on the Aggressive Lipid-lowering Treatment with Simvastatin on the Aged Patien

• 作 者: Xie Ying Bu Congya Zhou Yujie
• 机 构: Department of Geriatric Cardiology, Beijing A nzhen Hospital Affiliated of Capital University of Med
• 出 处: 岭南心血管病杂志（英文版）
• 发表日期: 2005年1期
• 关键词: Coronary heart disease Hypercho-lesterolemia Simvastatin Therapeutics

Objectives To find out the efficient dose and safety of simvastatin (Zocor) on the aged patients with coronary artery disease (CAD) for aggressive lipid-lowering treatment. Methods Select 95 aged patients with CAD combined with primary hyperlipemia and give them 20 mg/day of simvastatin for treatment. According to the therapeutic target of serum total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) regulate the dosage of simvastatin in follow-up. Observe 12～18 months. Results After treatment, the TC, LDL-C and triglycerides(TG)of the patients reduced by 40%, 52% and 26% respectively, while there was no significant change in high-density lipoprotein cholesterol (HDL-C). The apolipoprotein A1 arose by 14.4%, while the apolipoprotein B lowered by 25.0%. The ratio of LDL-C to HDL-C was reduced to 1.96. In the 6th month, the 12th month and the 18th month, respectively, 86%,93% and 95% of the patients took 10 mg/day of simvastatin and the result was their TC ≤ 140 mg/dL (3.7 mmol/L) and LDL-C ≤70 mg/dL(1.8 mmol/L).There was no special side-effect. Multi-factor analysis indicated the age of the patients was a significant factor affecting the adjustment of the dosage of simvastatin.Conclusions The therapeutic result of simvastatin on the aged patients with CAD for aggressive lipid-lowring treatment is definite, safe and the dose is lower as well.